(Q40332957)

19 September 2017

title

Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo (English)

1 reference

19 September 2017

Biglari A

1

1 reference

19 September 2017

Southgate TD

series ordinal

2

1 reference

19 September 2017

Fairbairn LJ

series ordinal

3

1 reference

19 September 2017

Gilham DE

series ordinal

4

1 reference

19 September 2017

publication date

1 April 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

13

1 reference

19 September 2017

issue

7

1 reference

19 September 2017

page(s)

602-610

1 reference

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Phase I/II trial of autologous activated macrophages in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Fc receptors are required in passive and active immunity to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Phage libraries for generation of clinically useful antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

7 January 2021

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

7 January 2021

Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

7 January 2021

Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

7 January 2021

Functional expression of chimeric receptor genes in human T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

7 January 2021

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302706

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302706

1 reference

Dimensions Publication ID

19 September 2017

1020426927

0 references

1 reference